← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 60.4% to $268.1M, while Net income increased 3186.6% to $124.5M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $268.1MOK
- Profitability — Net income $124.5MOK
- Cash generation — Free cash flow $48.9MOK
- Accounting — Formula-grey distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 0 buys; 20 sells in 365 daysNote
- Capital — share repurchases were $15.0MNote
Business
LIGAND PHARMACEUTICALS INC: TR-Beta Thyroid hormone receptor beta Vernalis Ligand UK Limited (f/k/a Vernalis plc) Verona Verona Pharma plc Viking Viking Therapeutics Xi'an Xintong Xi'an Xintong Pharmaceuticals Research Co.
Where the revenue comes from
Fiscal 2025, as LIGAND PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Royalties$161.0M
- Contract Revenue$66.9M
- Contract revenue and income$66.9M
- Captisol$40.2M
Leadership changes
From LIGAND PHARMACEUTICALS INC's own filings, the day they're filed.
- Matthew Korenberg · departureeff. 2024-08-02
- Martine Zimmermann · President · appointmenteff. 2023-09-22
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about LIGAND PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.